Welcome to our dedicated page for Proqr Therapeuti news (Ticker: PRQR), a resource for investors and traders seeking the latest updates and insights on Proqr Therapeuti stock.
ProQR Therapeutics N.V. reports developments as a clinical-stage biopharmaceutical company built around its proprietary Axiomer™ RNA editing platform. The technology uses ADAR-mediated RNA editing to make single-nucleotide changes in RNA, with pipeline updates centered on AX-0810 and additional programs across rare and prevalent diseases with unmet need.
Recurring company news includes scientific conference presentations, investor and analyst events, clinical-program updates, development-candidate selections, AI-enabled discovery initiatives, and collaborations such as Ginkgo Bioworks and Eli Lilly. ProQR also reports annual operating and financial results, annual general meeting materials, board composition changes, and other governance matters tied to its Nasdaq-listed public-company profile.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ProQR Therapeutics NV (Nasdaq: PRQR) announced its participation in several upcoming investor conferences to discuss its innovative RNA therapies using the Axiomer® RNA editing technology platform. Key events include:
- Van Lanschot Kempen Life Sciences Conference – April 26, Amsterdam (1x1 meetings only)
- JMP Securities Life Sciences Conference – May 16, New York (Fireside chat at 12:30 PM EDT)
- Stifel 2023 Tailoring Genes: Genetic Medicines Day – May 30, Virtual (Fireside chat, time TBC)
Details on presentations and webcasts will be available on the company’s website. ProQR is focused on advancing RNA therapies that address both rare and common diseases, utilizing its unique Axiomer® technology for precise RNA editing.
ProQR Therapeutics NV (Nasdaq: PRQR) announced its Annual General Meeting (AGM) of Shareholders scheduled for May 17, 2023, at 16:00 CET, in Amsterdam. Key updates include the nomination of Begoña Carreño and Theresa Heggie to the Supervisory Board, along with Bart Filius for re-election. Notably, Antoine Papiernik will rotate off the Board. Carreño brings over 20 years of experience in pharmaceutical development and strategy from Novartis, while Heggie has a strong background in commercial operations at Alnylam Pharmaceuticals. ProQR focuses on transformative RNA therapies utilizing its proprietary Axiomer® RNA editing technology, aiming to provide innovative treatment options for diseases with unmet needs.